Karyopharm's selinexor gets Priority Review for penta-refractory MM

FDA granted Priority Review to an NDA from Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for selinexor to treat penta-refractory

Read the full 177 word article

User Sign In